Early Versus Late Ofatumumab (Kesimpta ®) Use in Austrian RMS-Patients Over 2 Years
Condition: Relapsing Multiple Sclerosis Intervention: Other: Ofatumumab Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Austria Health | Research